Cyclopamine

For research use only.

Catalog No.S1146 Synonyms: 11-deoxojervine

58 publications

Cyclopamine Chemical Structure

CAS No. 4449-51-8

Cyclopamine (11-deoxojervine) is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 370 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Cyclopamine has been cited by 58 publications

Purity & Quality Control

Choose Selective Hedgehog/Smoothened Inhibitors

Biological Activity

Description Cyclopamine (11-deoxojervine) is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.
Targets
Smoothened [1]
(TM3Hh12 cells)
46 nM
In vitro

Cyclopamine inhibits the Hedgehog signaling pathway with an IC50 of 46 nM, and blocks the activity of human Smo receptor expressed in CHO-K1 cells in [3H]Hh-Ag binding assay with an IC50 of 280 nM. [1] Cyclopamine significantly inhibits Hedgehog pathway activity in a dose-dependent manner in gut-derived tumor cell lines expressing Patched (PTCH) mRNA, and induces growth inhibition of those tumor cell lines by 75-95% at the concentration of 3 μM, but ineffective towards the colon tumor cells without PTCH mRNA expression, suggesting the effects of Cyclopamine treatment are Hedgehog pathway related rather than generally cytotoxic. [2] By blocking Hedgehog signaling through direct interaction with Smo, Cyclopamine (10 μM) inhibits the proliferation of SMOhigh Cyclopamine-responsive cell lines L3.6sl and Panc 05.04 by 75-80%, and increases the apoptosis by 2.5- to 3.5-fold, without affecting the BxPC3-SMOlow cell line. [3] Cyclopamine treatment significantly decreases of Snail mRNA and increasea E-cadherin transcripts in the E3LZ10.7 cell line. Independent of inhibition of cell growth, Cyclopamine treatment significantly inhibits the invasive phenotype of Hedgehog-dependent L3.6pl cells, causing a >500-fold reduction in the number of transmigrating cells, but not that of the Hedgehog-independent cell line Panc-1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OS-RC-2 M3Xybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlK2TWM2OD13Lki2OlYh|ryP MlTmV2FPT0WU
DOHH-2 MmrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrETWM2OD17LkO1Olg6KM7:TR?= NWHxWIlOW0GQR1XS
no-10 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3SNGdKSzVyPUmuPVA{QSEQvF2= MoG3V2FPT0WU
LS-513 Ml7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlr6TWM2OD1zMT6zOVQ4KM7:TR?= M{HEd3NCVkeHUh?=
ALL-PO M2T1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zYcGlEPTB;MUGuO|c{PCEQvF2= MW\TRW5ITVJ?
8-MG-BA MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfFTWM2OD1zMz6xNVI{KM7:TR?= MVjTRW5ITVJ?
RPMI-8402 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTF3Lki1N|ch|ryP NF\CbppUSU6JRWK=
EoL-1-cell Mnm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlG2TWM2OD1zOD61PVQ5KM7:TR?= Mk\MV2FPT0WU
NALM-6 M3rCcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4T2XGlEPTB;MUmuNFE3PyEQvF2= M4XGXHNCVkeHUh?=
DEL NWP0fWFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTJyLkG0O|Eh|ryP MoXKV2FPT0WU
SR M4TJeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1ftUWlEPTB;MkOuOlcyPSEQvF2= MnLNV2FPT0WU
697 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjhTXdXUUN3ME2yOk43OTV3IN88US=> NEe0[opUSU6JRWK=
COLO-829 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTrTWM2OD1{Nj64OFg{KM7:TR?= MYXTRW5ITVJ?
EVSA-T M1Lsfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTJ5LkW1OlEh|ryP NUnDU5VMW0GQR1XS
ATN-1 NHno[HJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3WxcmlEPTB;M{GuNlMzQSEQvF2= NWHrOFFsW0GQR1XS
L-363 M1HCNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\tRmZtUUN3ME2zNU44PDZzIN88US=> NVHQWWtpW0GQR1XS
LAMA-84 MlTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTN{LkWyNVEh|ryP M3jNbXNCVkeHUh?=
NOS-1 M2rpXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHe4WVdKSzVyPUO0MlI6PTZizszN NXrjbJptW0GQR1XS
BB30-HNC M{fqbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXuwTZc5UUN3ME2zOE4{OzB4IN88US=> M1X5RnNCVkeHUh?=
BC-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTN5Lkm3OFYh|ryP MnLSV2FPT0WU
IST-SL2 NEe1SJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1qyfWlEPTB;M{iuNlI1KM7:TR?= NHfQT|JUSU6JRWK=
D-392MG MoTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTRyLkKyNVUh|ryP NYnMeZo5W0GQR1XS
no-11 M3PCcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4O1cGlEPTB;NECuOVUzOSEQvF2= MkLiV2FPT0WU
LC4-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTRyLki3NVYh|ryP Mo\WV2FPT0WU
A388 NGnlToVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;DTWM2OD12Mj61PFQ5KM7:TR?= MYTTRW5ITVJ?
NTERA-S-cl-D1 M1H1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7FWFNKSzVyPUSyMlcxPzRizszN NWrHb4VnW0GQR1XS
CESS NYPqSY93T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33UeWlEPTB;NESuNlI{OiEQvF2= NV\nSIh5W0GQR1XS
RS4-11 Moq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7IbJlTUUN3ME20PU4xQTN6IN88US=> NFHzVItUSU6JRWK=
MS-1 MlLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHFfVgzUUN3ME21NE46OzVzIN88US=> NF;6SFBUSU6JRWK=
CTV-1 MnjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;CW5A4UUN3ME21NU4xPzRizszN MmXQV2FPT0WU
D-502MG NUHafGhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTDZYNxUUN3ME21NU43OjdzIN88US=> NITNV|FUSU6JRWK=
ML-2 MlfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGn2SXhKSzVyPUWyMlkyQTVizszN NF;XV5hUSU6JRWK=
SK-NEP-1 NGTQ[ZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjU[FBGUUN3ME21N{4{QTJ|IN88US=> MnHWV2FPT0WU
LOXIMVI Mmf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzseXdUUUN3ME21N{42QDh2IN88US=> M{DuOHNCVkeHUh?=
DJM-1 NFy2TWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXv1fGE3UUN3ME21Ok4{OzlzIN88US=> M{e4UHNCVkeHUh?=
GI-1 NIXIbpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PsWWlEPTB;NU[uOlE1QSEQvF2= M3\3SXNCVkeHUh?=
IST-MES1 M3X1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NID5[FFKSzVyPU[wMlU1QTNizszN NI\4U3VUSU6JRWK=
MV-4-11 NEHP[WlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTZyLk[1N|gh|ryP Mk\PV2FPT0WU
OVCAR-4 M3jRemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3SzRWlEPTB;NkOuOVY2PyEQvF2= M3nmNnNCVkeHUh?=
KE-37 NIf1[2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTZ4LkK2Olgh|ryP M1LNTXNCVkeHUh?=
D-542MG M{Toemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LId2lEPTB;NkiuOFE{PSEQvF2= MkW0V2FPT0WU
MHH-PREB-1 MlLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTd{Lki0OFEh|ryP MYXTRW5ITVJ?
MRK-nu-1 NVnkNpFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDSTWM2OD15Mz60O|A2KM7:TR?= NH;nfGVUSU6JRWK=
D-247MG MlrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfKTWM2OD15Mz61OFQzKM7:TR?= MoHtV2FPT0WU
OCI-AML2 NFewSYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfrbFBKSzVyPUe2Mlk{PjlizszN NV3EVlhCW0GQR1XS
LP-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LIcWlEPTB;OEKuPFc{OSEQvF2= NXTPe2t2W0GQR1XS
HCC1599 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnX1TWM2OD16ND6yPFM4KM7:TR?= NIDmPXJUSU6JRWK=
KARPAS-45 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTh2Lk[5PVIh|ryP M2\6bHNCVkeHUh?=
BE-13 NFm1cpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2npTWlEPTB;OUmuNFQ4PyEQvF2= NHPBVYRUSU6JRWK=
GCIY MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TLZ2lEPTB;OUmuNFk2PCEQvF2= M{jobnNCVkeHUh?=
BV-173 M1nsbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHRVpZKSzVyPUGwNE4{OjVizszN NUDYXI5qW0GQR1XS
LB2518-MEL MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHRS5NMUUN3ME2xNFAvPzh7IN88US=> MXfTRW5ITVJ?
KS-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3aTWM2OD1zMEGuOlM6KM7:TR?= NF[ydIhUSU6JRWK=
MOLT-16 NVfIS|Y2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{m4SWlEPTB;MUC0Mlk5PiEQvF2= MXPTRW5ITVJ?
NCI-H1770 NX3uZ|R3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG[0O4pKSzVyPUGwPE44QDRizszN M{jnenNCVkeHUh?=
NCI-H82 MnroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17NW2lEPTB;MUGwMlk4PiEQvF2= MlTpV2FPT0WU
NCCIT NXfUN|BIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn33TWM2OD1zMUKuOVI6KM7:TR?= MWTTRW5ITVJ?
KALS-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13sN2lEPTB;MUG1Mlk1OSEQvF2= MXfTRW5ITVJ?
LB2241-RCC MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLIbnBKSzVyPUGxOk43PzlizszN MYHTRW5ITVJ?
HH MnfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHiVnpKSzVyPUGxO{4{QTVizszN NVfISGRuW0GQR1XS
HD-MY-Z NX:2V3k1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPLTWM2OD1zMUiuOFg5KM7:TR?= NYfheY4yW0GQR1XS
EB-3 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTFdWlWUUN3ME2xNlMvODl2IN88US=> NGrQVJBUSU6JRWK=
BL-70 NF\US2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTF{Mz6xNlch|ryP MUHTRW5ITVJ?
K-562 NHzPbXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYj4eItkUUN3ME2xNlYvOjR3IN88US=> MYXTRW5ITVJ?
HT-144 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{e2VGlEPTB;MUOzMlE3PCEQvF2= NFvRNoxUSU6JRWK=
PF-382 MknzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDiTWM2OD1zM{SuN|YyKM7:TR?= NWjEXWJvW0GQR1XS
RPMI-8226 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LGcmlEPTB;MUO1MlA1PSEQvF2= NUTsSJZkW0GQR1XS
NCI-H1355 Mk\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXT4e5lVUUN3ME2xN|UvPTh5IN88US=> NXPrWVFpW0GQR1XS
LXF-289 M1nzcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLCTWM2OD1zM{muO|gyKM7:TR?= M4n2c3NCVkeHUh?=
NCI-H69 NF:xZolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\rTWM2OD1zNEKuPVMzKM7:TR?= NEC4TYNUSU6JRWK=
SK-MEL-1 MnTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnOwTWM2OD1zNEeuNVMh|ryP NWHmWWlmW0GQR1XS
KARPAS-299 NYDFfFVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fZemlEPTB;MUS5MlEzKM7:TR?= M2\MUXNCVkeHUh?=
GB-1 NIDJZ4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXxTWM2OD1zNEmuN|IzKM7:TR?= MV7TRW5ITVJ?
CMK MoW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\xcGxKSzVyPUG0PU42OTVizszN MkPXV2FPT0WU
MPP-89 M3jjN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TD[WlEPTB;MUW2MlA{PSEQvF2= NYrHN5NwW0GQR1XS
KU812 NEDtUHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vxN2lEPTB;MU[xMlkxOiEQvF2= MXnTRW5ITVJ?
REH MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTF4Mj6xNlUh|ryP M2PwUnNCVkeHUh?=
NEC8 NGHobnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTF4NT6wNlYh|ryP MYfTRW5ITVJ?
KP-N-YS MnjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlz1TWM2OD1zNkiuN|k2KM7:TR?= NEL3SIFUSU6JRWK=
Ramos-2G6-4C10 NVnKVGNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\LTWM2OD1zNkmuPVE2KM7:TR?= MUDTRW5ITVJ?
Becker M2T1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4D4OGlEPTB;MUe0MlE5KM7:TR?= Mof4V2FPT0WU
LB647-SCLC NGfzfJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XBVWlEPTB;MUe1Mlg1PSEQvF2= NUL0TopuW0GQR1XS
LU-139 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHl[3E3UUN3ME2xO|gvODF7IN88US=> NX3SSVYxW0GQR1XS
QIMR-WIL MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTF5OT62OFYh|ryP NHPTU2JUSU6JRWK=
NCI-H1395 NVy3[IZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULrflMyUUN3ME2xO|kvQTl4IN88US=> M3jlbXNCVkeHUh?=
NOMO-1 NXHYNWRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX6wTVF[UUN3ME2xPFIvQDVizszN NFmzToFUSU6JRWK=
GI-ME-N MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[wfVVKSzVyPUG4O{46PjlizszN NIX5SnZUSU6JRWK=
KMS-12-PE MnLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XlbmlEPTB;MUi5MlI4OyEQvF2= NUf5eYVGW0GQR1XS
Daudi MknQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTF7MT6xNlgh|ryP MV3TRW5ITVJ?
LB996-RCC NHf1eIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTF7MT62PVkh|ryP NYCzfHZjW0GQR1XS
NCI-H2107 NFLNOZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLuTWM2OD1zOUOuO|M6KM7:TR?= NFHrWFBUSU6JRWK=
SK-PN-DW MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofzTWM2OD1zOUSuO|E6KM7:TR?= NV;ib3JXW0GQR1XS
MC-CAR NX;IPWNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPqTWM2OD1{MEKuNlU{KM7:TR?= NGP4UohUSU6JRWK=
SNB75 NHy3N|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnm4TWM2OD1{MkGuPVQh|ryP MYnTRW5ITVJ?
ES4 NHnCeo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnJfJJyUUN3ME2yNlMvPzh|IN88US=> NH\GZYJUSU6JRWK=
KARPAS-422 NU\rUYk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUS4cVMxUUN3ME2yNlgvOzV{IN88US=> NF3TXGRUSU6JRWK=
NCI-H1648 M2q1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DacWlEPTB;MkK5MlQ5QSEQvF2= NFHWdnNUSU6JRWK=
ES6 M4PsUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUD0fXN4UUN3ME2yN|kvPDNizszN MYXTRW5ITVJ?
KNS-81-FD Ml3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33hZmlEPTB;MkSxMlE6PyEQvF2= MX\TRW5ITVJ?
JAR Mmr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLEXXRKSzVyPUK1Ok4zOjVizszN M{G2fnNCVkeHUh?=
NB1 M{DBXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Lv[WlEPTB;Mk[wMlUyPiEQvF2= M{jVNXNCVkeHUh?=
D-336MG NYLaeGhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\JZWJKSzVyPUK2NE43QThizszN NYLFNY9WW0GQR1XS
BC-3 M1LrXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTJ4NT6xO|gh|ryP NFjRT3VUSU6JRWK=
HCC2218 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;yOo5KSzVyPUK2Ok41OTVizszN NWi0[pU5W0GQR1XS
TE-9 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTJ4Nj62Nlch|ryP MmfJV2FPT0WU
LB1047-RCC M3;VTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELuUY5KSzVyPUK2Ok44PTNizszN NV;MeZc6W0GQR1XS
CTB-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TNWWlEPTB;Mk[5Mlk4OyEQvF2= NEHGXVVUSU6JRWK=
NB7 NVjv[|dDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTJ5MTFOwG0> M3nqdnNCVkeHUh?=
ST486 M3zj[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTJ5Nz60NVIh|ryP M2PBWnNCVkeHUh?=
HCC1187 MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XUeGlEPTB;MkiyMlgyOSEQvF2= NH3BZ45USU6JRWK=
NCI-SNU-16 MnPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLEcIt6UUN3ME2yPFQvOjR6IN88US=> NXrBUGFVW0GQR1XS
COR-L279 MnTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTJ7MT61PFQh|ryP MnrLV2FPT0WU
ES8 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\UVWlEPTB;Mkm0MlE5OiEQvF2= NWXiTo1NW0GQR1XS
U-698-M M2WxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XmRmlEPTB;Mkm4MlI1OyEQvF2= NHT4bndUSU6JRWK=
HEL MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTNyOT6xOFkh|ryP MX7TRW5ITVJ?
KINGS-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXJdYRGUUN3ME2zNVAvPjd2IN88US=> NVzjOpNTW0GQR1XS
KY821 NWPyNFl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTN|Nj61PVUh|ryP NGfwVItUSU6JRWK=
MZ1-PC MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHXTWM2OD1|NEWuOlE5KM7:TR?= NW\mNmREW0GQR1XS
LS-411N NVfaVlU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\tdJFKSzVyPUO1OE43PiEQvF2= M3TkO3NCVkeHUh?=
SIG-M5 NXHWS3dvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17LdmlEPTB;M{W5Mlc5OiEQvF2= MnfTV2FPT0WU
HT MnvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHwRo5KSzVyPUO2O{44OTFizszN MnXUV2FPT0WU
HC-1 MoDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTN4Nz63PFch|ryP MmPuV2FPT0WU
NCI-H1694 NV\uOHlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mke0TWM2OD1|N{KuPVM1KM7:TR?= NYG4VZJUW0GQR1XS
BB65-RCC NVz6OFlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoP3TWM2OD1|N{[uNlQ2KM7:TR?= MUPTRW5ITVJ?
HAL-01 Ml;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTN5OT64N|gh|ryP NYPGSXRzW0GQR1XS
ARH-77 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NED2c5VKSzVyPUO5OE4xODhizszN NGPST5RUSU6JRWK=
MZ7-mel MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTN7Nz6yN|Mh|ryP M3fwSXNCVkeHUh?=
SIMA MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkGxTWM2OD12MEOuPVM{KM7:TR?= MoTGV2FPT0WU
DG-75 NUP1PXdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTRzNT62PVgh|ryP MXTTRW5ITVJ?
HUTU-80 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTRzOT6xPFUh|ryP MkC2V2FPT0WU
KNS-42 NVriPZpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\vcVBKSzVyPUSyOU45OTVizszN NHXJOFlUSU6JRWK=
SH-4 M1S3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXP6VJdGUUN3ME20NlcvPTZ3IN88US=> NWrPPGUyW0GQR1XS
L-540 MoX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTR|MT6wN|Eh|ryP NH7xXlVUSU6JRWK=
NB10 M{nLfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTR2MT6yN|Qh|ryP NH\PWVFUSU6JRWK=
ES1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nRXmlEPTB;NEWyMlc2OyEQvF2= MXfTRW5ITVJ?
KMOE-2 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmX0TWM2OD12NU[uO|EyKM7:TR?= M1PDXnNCVkeHUh?=
MC116 NIL0NWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlSxTWM2OD12NUiuNVE3KM7:TR?= NVvmdJExW0GQR1XS
RCC10RGB MnjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\TfWNRUUN3ME20OlAvODB3IN88US=> NUPBZWxFW0GQR1XS
RL95-2 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFP3b|hKSzVyPUS2NE4zOzdizszN MUTTRW5ITVJ?
Raji NFPHSoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jiN2lEPTB;NE[4MlE1OyEQvF2= M1zZbXNCVkeHUh?=
CAS-1 NUTRfHZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFe2fpJKSzVyPUS3Nk4xPzNizszN MUTTRW5ITVJ?
Calu-6 NF3pVolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTR5NT6yOlUh|ryP M4XEcnNCVkeHUh?=
KG-1 NWnoOIZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PsXGlEPTB;NEe4MlQ1KM7:TR?= MXvTRW5ITVJ?
LB771-HNC M1nqd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTR6Mj6yN|Ih|ryP MYDTRW5ITVJ?
ACN MmLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\lTWM2OD12OUOuOVk6KM7:TR?= M4m5THNCVkeHUh?=
KM12 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTR7Nj61PFkh|ryP M1zWXXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
NF-κB / Cyclin D1 / MMP2 / MMP9; 

PubMed: 23599805     


Whole cell lysates were prepared, and 50 μg proteins were resolved using SDS-PAGE, followed by immunoblotting with the indicated specific antibodies against NF-κB, cyclin D1, MMP2 and MMP9. 

Gli1 / TGF-β1 / CXCR4; 

PubMed: 26137001     


Western blotting demonstrated that Gli1, TGF-β1 and CXCR4 protein expression levels were downregulated in the AGS cells treated with cyclopamine for 24 h.

Snail / E-cadherin / Slug / Vimentin ; 

PubMed: 26859575     


SW1736 and WRO82 cells were incubated in the presence of vehicle (0.5% DMSO) or the indicated concentrations of cyclopamine or GANT61 for 72 hr. The cells were harvested and analyzed for the expression of several genes involved in EMT.

23599805 26137001 26859575
Immunofluorescence
Vimentin; 

PubMed: 24553082     


Vimentin protein expression was reduced following treatment with cyclopamine (20 μmol/L; 72 h), detected by immunocytochemistry.

PCNA / β-catenin; 

PubMed: 28747625     


Immunofluorescence images demonstrating the distribution of PCNA or β-catenin in EH cells pre-treated with cyclopamine in presence and absence of estrogen for 24 h. Experiments were repeated at least three times.

24553082 28747625
In vivo Administration of Cyclopamine at dose of 50 mg/kg/day for 22 days eradicates the HUCCT1 xenografts in mice with no obvious adverse effects. [2] Cyclopamine treatment at dose of 1.2 mg for 7 days induces significant apoptosis of tumor cells and decreases the tumor mass by 50-60% in Panc 05.04- and L3.6sl-derived tumors, respectively, but not in the BxPC3-SMOlow tumors. [3] Administration of Cyclopamine alone profoundly inhibits tumor metastases in xenografts of E3LZ10.7 and L3.6pl, and completely abrogates metastases when in combination of gemcitabine. [4]

Protocol

Kinase Assay:[1]
- Collapse

Hedgehog cell assay:

This assay measures the end stage of the Hh signaling pathway, that is, the transcriptional modulation of Gli, using Luciferase as readout (Gli-Luc assay). Cyclopamine is prepared for assay by serial dilution in DMSO and then added to empty assay plates. TM3Hh12 cells (TM3 cells containing Hh-responsive reporter gene construct pTA-8xGli-Luc) are resuspended in F12 Ham's/DMEM (1:1) containing 5% FBS and 15 mM Hepes pH 7.3, added to assay plates and incubated with Cyclopamine for approximately 30 minutes at 37 °C in 5% CO2. 1 nM Hh-Ag 1.5 is then added to assay plates and incubated at 37 °C in the presence of 5% CO2. After 48 hours, either Bright-Glo or MTS reagent is added to the assay plates and luminescence or absorbance at 492 nm is determined. IC50 value, defined as the inflection point of the logistic curve, is determined by non-linear regression of the Gli-driven luciferase luminescence or absorbance signal from MTS assay vs log10 (concentration) of Cyclopamine using the R statistical software pack
Cell Research:[2]
- Collapse
  • Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, and HCT116
  • Concentrations: Dissolved in DMSO, final concentration 3 μM
  • Incubation Time: 4 days
  • Method: Cells are exposed to Cyclopamine in 96-well plates. Cell viability is measured by MTS (soluble tetrazolium salt) assay. Viable cell mass is determined by optical density measurements at 490 nm (OD490) at 2 and 4 days using the CellTiter96 colorimetric assay. Relative growth is calculated as OD (day 4)﹣OD (day 2)/OD (day 2).
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: Athymic (nude) mice inoculated subcutaneously with HUCCT1 cells
  • Dosages: 50 mg/kg/day
  • Administration: Subcutaneous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMF 10 mg/mL warmed (24.29 mM)
Ethanol 2 mg/mL warmed (4.85 mM)
DMSO Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 411.62
Formula

C27H41NO2

CAS No. 4449-51-8
Storage powder
in solvent
Synonyms 11-deoxojervine
Smiles CC1CC2C(C(C3(O2)CCC4C5CC=C6CC(CCC6(C5CC4=C3C)C)O)C)NC1

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo use in mice?

  • Answer:

    One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

Related Hedgehog/Smoothened Products

Tags: buy Cyclopamine | Cyclopamine supplier | purchase Cyclopamine | Cyclopamine cost | Cyclopamine manufacturer | order Cyclopamine | Cyclopamine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID